RSS

Raxone

Swiss specialty pharmaceutical company, Santhera Pharmaceuticals, has received a negative opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its revised marketing authorisation application for Raxone in DMD Read more

News

Santhera Pharmaceuticals has announced that the MHRA has granted a positive scientific opinion through the Early Access to Medicines Scheme (EAMS) to Raxone (idebenone) for patients with respiratory function decline not taking glucocorticoids in DMD Read more

News